Spica Healthcare — Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsMedical Oncology & ChemotherapyCirculating Tumor DNA (ctDNA) & Minimal Residual Disease (MRD): Liquid Biopsy for Post-Surgical Recurrence Surveillance
Medical Oncology & Chemotherapy

Circulating Tumor DNA (ctDNA) & Minimal Residual Disease (MRD): Liquid Biopsy for Post-Surgical Recurrence Surveillance

10 min read
Sep 2, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #142

Clinical Summary & Key Takeaways

A revolutionary molecular oncology review on Liquid Biopsy and Minimal Residual Disease (MRD), evaluating tumor-informed Next-Generation Sequencing (Signatera, Guardant Reveal), predicting recurrence 8–10 months before CT scans, and guiding adjuvant chemotherapy de-escalation.

CRITICAL CLINICAL RED FLAG: Detecting microscopic persistent circulating tumor DNA (ctDNA-positive status) in a routine blood draw following curative cancer surgery predicts disease recurrence with a >95% positive predictive value, demanding early systemic therapy.

1. The Paradigm Shift: From Anatomic Scans to Molecular MRD

Following curative-intent cancer surgery (for colorectal, lung, breast, or bladder cancers), a significant subset of patients harbor microscopic occult micrometastases that are completely invisible on standard CT/MRI. Circulating tumor DNA (ctDNA)—short fragments of cell-free DNA shed into peripheral blood by apoptotic tumor cells—provides a direct biomarker of Minimal Residual Disease (MRD).

  • Tumor-Informed Assay: Whole-exome sequencing of the resected surgical tumor tissue identifies 16 patient-specific clonal somatic mutations.

  • Ultra-Sensitive Digital PCR / NGS: Tracks these customized mutation markers in serial plasma blood draws with a sensitivity limit of 0.01%.

2. Guiding Adjuvant Chemotherapy Decision-Making (DYNAMIC Trial)

The landmark DYNAMIC phase II trial in Stage II colon cancer demonstrated that ctDNA-guided adjuvant chemotherapy reduced chemotherapy usage by nearly 50% without compromising recurrence-free survival compared to standard management.

"Liquid biopsy ctDNA analysis allows us to look into the patient's bloodstream with molecular precision, sparing cured patients unnecessary chemotherapy while catching microscopic recurrence months before scans can see it." — Dr. Neha Gupta
Spica Healthcare Clinical & Surgical Protocol Illustration #142
Spica Healthcare Clinical & Surgical Protocol Illustration #142

3. Early Recurrence Warning Window (Lead-Time Advantage)

Serial ctDNA monitoring detects molecular relapse with a median lead time of 8 to 10 months ahead of conventional radiographic CT/PET imaging, enabling intervention when tumor burden is low and curable.

CLINICAL CAUTION: Traditional radiologic CT and PET scans have a detection limit of approximately 5 mm (containing ~100 million cancer cells); ctDNA detects microscopic tumor burden down to a single molecule per milliliter of plasma.

4. Monitoring Treatment Response in Advanced Metastatic Cancer

A rapid drop in ctDNA levels within 2 to 4 weeks of initiating immunotherapy or targeted therapy serves as an early surrogate for deep radiological response.

5. Peer-Reviewed References & Clinical Guidelines

1. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer (DYNAMIC Trial) — NEJM, 2022; 386: 2261-2272.

2. Minimal Residual Disease Detection in Solid Tumors using ctDNA: Clinical Applications and Future Directions — Nature Reviews Clinical Oncology, 2023; 20(4): 230-248.

Frequently Asked Patient Questions

Limb Salvage with modular titanium megaprosthesis removes the tumor completely while preserving the limb, allowing patients to walk, work, and maintain full social independence without the physical disability of an artificial limb.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Senior Consultant & Clinical Director — Medical Oncology

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director — Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.